Abstract: Rosuvastatin is an HMG-CoA reductase inhibitor widely used for treating hypercholesterolaemia. We investigated whether genetic polymorphisms in solute carrier organic anion transporter 2B1 (SLCO2B1) affect the lipid-lowering effect of rosuvastatin in healthy adults with elevated low-density lipoprotein (LDL). This study included 18 volunteers with LDL levels above 130 mg/dL. Rosuvastatin (20 mg) was administered once a day for 8 weeks. Blood samples were drawn before and after the 8-week treatment to measure changes in lipid levels. The presence of single nucleotide polymorphisms (SNPs) of SLCO2B1 (c.935G>A and c.1457C>T), SLCO1B1 (c.521C>T, c.388A>G and c.-11187G>A) and ABCG2 (c.421C>A) was determined by genotyping. Responses to rosuvastatin were compared between wild-type and variant genotypes using permutation test on each polymorphism. In volunteers with SLCO2B1 c.935G>A (rs12422149) variant, rosuvastatin was less effective at lowering LDL (mean % decrease: GG 62.8% GA 50.6% AA 49.3%, p = 0.012) and apoprotein B (mean % decrease: GG 52.1% GA 42.8% AA 42.8%, p = 0.036). Regarding SLCO2B1 c.1457C>T (rs2306168) SNP, there was no significant difference between wildtype and variant genotypes. This study demonstrated that SLCO2B1 c.935G>A (rs12422149) polymorphism influenced the lipidlowering effects of rosuvastatin in volunteers with hypercholesterolaemia.
Ion transporters in various tissues play important roles in the absorption, distribution and elimination of drugs. Transporters can be subdivided into two categories, namely influx transporters taking drugs into cells and efflux transporters pumping drugs out of cells [1, 2] . The solute carrier organic anion transporters (SLCOs), also known as organic transporting polypeptides (OATPs), constitute a major influx transporter family responsible for uptake of a broad range of drugs. The SLCO gene family consists of 11 members including SLCO1B1, SLCO1B3, SLCO1A2 and SLCO2B1, which are the most wellcharacterized SLCOs [2, 3] .
Among SLCO family members, SLCO2B1 and SLCO1A2 transporters expressed in the intestine have been reported to play an important role in the absorption of drug substrates from the intestinal lumen [3, 4] . Several single nucleotide polymorphisms (SNPs) have been reported in SLCO2B1, including c.935G>A (rs12422149), c.1457C>T (rs2306168), c.1175C>T (rs1621378) and c.601G>A (rs35199625) [5] . These SLCO2B1 polymorphisms seem to have variable effects on the pharmacokinetics of substrate drugs. For fexofenadine and celiprolol, SLCO2B1 c.1457C>T (rs2306168) polymorphism had a significant effect on drug pharmacokinetics, showing a decrease in systemic exposure by 34-50% [6] [7] [8] . For montelukast, Mougey et al. [9] reported a decrease in the plasma concentrations of montelukast among SLCO2B1 c.935G>A (rs12422149) carriers, although this finding was not consistently observed in other studies [10] [11] [12] .
In this paper, we report the role of genetic polymorphisms in SLCO2B1 on the lipid-lowering effects of rosuvastatin, an HMG-CoA reductase inhibitor widely used for treating hypercholesterolaemia. An in vitro study has shown that rosuvastatin is translocated by various transporters including SLCO2B1, SLCO1B1 located in hepatocyte and ABCG2 located in enterocyte and hepatocyte [13] . Whereas the association between genetic polymorphisms in SLCO1B1 or ABCG2 and pharmacokinetics or pharmacodynamics of rosuvastatin in human beings have been relatively well-established [14] [15] [16] [17] , few clinical studies have investigated the effects of SLCO2B1 polymorphisms on rosuvastatin pharmacokinetics or efficacy.
We compared the lipid-lowering effect of rosuvastatin between SLCO2B1 genotypes after 8-week treatment in healthy adults with elevated low-density lipoprotein (LDL) cholesterol.
Materials and Methods
Study population and design. This study included male and female volunteers, aged 20-55 years, with LDL above 130 mg/dL. Exclusion criteria were as follows: any marked past medical or medication Author for correspondence: Joo-Youn Cho, College of Medicine, Seoul National University, 101 Daehakro, Jongno-Gu, Seoul 110-744, Korea (e-mail joocho@snu.ac.kr).
history, and any abnormal findings on a physical examination, vital sign evaluation, 12-lead electrocardiogram or clinical laboratory tests, except for LDL levels. Also, volunteers were excluded from the study if (i) they had taken any lipid-lowering agent in the prior 6 weeks, (ii) they were unable to stop medications that could affect lipid levels or (iii) they had participated in other clinical trials within 3 months.
This study was conducted in one arm. Volunteers received rosuvastatin (20 mg) once a day for 8 weeks. Blood samples were drawn to evaluate rosuvastatin-induced changes in blood lipids, including total cholesterol, LDL, HDL, triglyceride and apoprotein B (apoB). Blood samples for lipid analysis were collected before the first dose on day 1 and before the morning dose at 2, 4, 6 and 8 weeks of rosuvastatin treatment. Blood samples for plasma rosuvastatin concentrations were also collected before the first dose, on day 1, and before dose administrations at 2, 4, 6 and 8 weeks after starting rosuvastatin treatment. Blood samples for genotyping were collected on day 1 before dosing.
The Institutional Review Board of Seoul National University Hospital approved the study protocol (IRB No. 1108-123-375), and informed consent was obtained from all volunteers before study enrolment. All procedures were performed in accordance with the recommendations of the Declaration of Helsinki. Furthermore, the study was conducted in compliance with Good Clinical Practice and other applicable laws and regulatory requirements currently established in South Korea.
Genotyping. Single nucleotide polymorphisms in SLCO2B1, SLCO1B1 and ABCG2 were determined with a TaqMan Allelic Discrimination Assay performed on an AB 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Briefly, genomic DNAs were extracted from 200 lL of whole peripheral blood drawn from each volunteer with a QIAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden, Germany). Then, a PCR mixture (total volume, 10 lL) was prepared with 5 lL of 29 TaqMan Genotyping Master Mix, 0.5 lL of 209 Drug Metabolism Genotyping Assay Mix, 3.5 lL of DNase-free water and 1 lL of genomic DNA. Genotyping assays were performed to identify the following SNPs (Assay IDs indicate the TaqMan Genotyping Assays; Applied Biosystems): SLCO2B1 c.935G>A (rs12422149, Assay ID: C_3101331_10), SLCO2B1 c.1457C>T (rs2306168, Assay ID: C_16193013_20), SLCO1B1 c.521C>T (rs4149056, Assay ID: C_30633906_10), SLCO1B1 c.388A>G (rs 2306283, Assay ID: C_1901697_20), SLCO1B1 c.-11187G>A (rs 4149015, Assay ID:C_32325356_10) and ABCG2 c.421C>A (rs2231142, Assay ID: C_15854163_70). The assays were conducted with the following PCR protocol: initial denaturation at 95°C for 10 min., and 50 cycles of denaturation at 92°C for 15 sec. and annealing/extension at 60°C for 1 min. After amplification, the allelic discrimination results were determined by performing an end-point read. Analyses were performed with 7500 Real-Time PCR System software versions 2.0.1 and 2.0.6 (Applied Biosystems). Haplotypes of SLCO1B1 were defined based on the presence of c.388A>G, c.521T>C and c.-11187G>A polymorphisms alone or in combination as follows: SLCO1B1*1a (wild-type), *1b (c.388G), *5 (c.521C), *15 (c.388G and c.521C) or *17 (c.388G, c.521C and c.-11187G>A).
Determination of rosuvastatin concentrations. Plasma concentrations of rosuvastatin were determined with a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, with glipizide as an internal standard. Briefly, plasma (200 lL), diethyl ether (1.5 mL) and glipizide (50 lL at 10 ng/mL) were mixed thoroughly and centrifuged at 13,0009 g for 5 min. After evaporating the supernatant, the residue was reconstituted with 100 lL of 50% methanol in 1 M acetic acid and injected into the LC-MS/MS system. The lower limit of quantification (LLOQ) for rosuvastatin was 0.2 ng/ mL with a linear calibration range of 0.2-80 ng/mL. Each analytical batch had six quality control (QC) samples of known values; that is, two QC samples each, for low, intermediate and high concentrations. The analytical results were accepted only when more than four of six QC sample concentrations were determined within 15% of known values. Intra-and interday accuracies were 104.3% and 109.8%, respectively; intra-and interday precisions varied with <5.6 CV%.
Statistical analysis. Baseline characteristics (age, sex, BMI, SLCO1B1 genotype and ABCG2 genotype) were compared between volunteers with different SLCO2B1 genotypes with Mann-Whitney U-test or Fisher's exact test according to the type of data.
The trough level and changes in lipid levels from baseline were compared between wild-type and variant genotypes with a permutation test to overcome the limitation of small sample size [18] . IBM SPSS Statistics TM 21 (version 21; Datasolution Inc., Seoul, Korea) was used for the analysis of baseline volunteer characteristics and R software version 3.2.5 (R Foundation for Statistical Computing, Vienna, Austria) for the comparison between genotypes. The two-sided level of statistical significance was set at 0.05. 
Results

Study population.
In this study, a total of 21 were enrolled. Among them, 19 volunteers completed the study and two volunteers dropped out; one withdrew consent before starting dosing, and the other was lost to follow-up after day 15. As the DNA sample of a volunteer who completed the study was lost, genotyping and further data analysis were performed for the 18 volunteers.
Individuals with wild-type and variant SLCO2B1 genotypes were not significantly different in age, sex, BMI or the distributions of SLCO1B1 and ABCG2 genotypes (table 1) .
Trough concentration.
Trough concentrations of plasma rosuvastatin after 8 weeks of treatment were used in comparison. The trough concentrations were not significantly different between volunteers with wildtype and those with variant genotypes. Notably, one volunteer Table 2 . Trough concentrations of plasma rosuvastatin in volunteers (N = 18) with different genotypes. The trough levels were compared with permutation test between wild-type (wt) and the variant genotypes. with SLCO1B1 *17/*17 showed a trough concentration of 18.8 ng/mL, which was 6.3 times and 4.9 times higher than those of wild-type and heterogeneous variant volunteers, respectively (table 2) .
Lipid profiling.
Total cholesterol, LDL and triglyceride levels were decreased, and HDL levels were increased with rosuvastatin treatment. The apoA1 levels were increased, and apoB levels were decreased after rosuvastatin treatment ( fig. 1 ). When the mean % changes of six kinds of lipid levels were compared between wild-type and variant genotypes after 8 weeks of treatment, volunteers with SLCO2B1 c.935G>A (rs12422149) genotype showed significantly lower mean % changes in LDL and apoB levels than those with wild-type did. In contrast, volunteers with ABCG2 c.421C>A (rs2231142) genotype exhibited significantly higher mean % changes in LDL, apoB and total cholesterol levels than those with the wild-type genotype did (table 3, fig. 2 ). Genetic polymorphisms of SLCO1B1 and SLCO2B1 c.1457C>T (rs2306168) were not associated with any significant differences in mean % changes in lipids (table 3) .
Safety profiles.
Of 20 volunteers who received rosuvastatin at least once, nine volunteers reported a total of 41 adverse events. Three cases of musculoskeletal pain were reported by two volunteers. The genotypes of a volunteer with musculoskeletal pain were SLCO2B1 c.935G>A (rs12422149) GA, SLCO2B1 c.1457C>T (rs2306168) CT, SLCO1B1 *1a/*1b and ABCG2 c.421C>A (rs2231142) AA. The other volunteer who reported the musculoskeletal pain did not agree to provide genotype information and was lost to follow-up. Other adverse events reported at least in two cases were myalgia, cough, fatigue, oropharyngeal pain, rhinorrhoea, sputum retention, nasal congestion, constipation, pruritus and back pain (table 4) . In one volunteer, elevated creatine phosphokinase (CPK) of 2919 IU/L was reported on day 43, which returned to a normal level on a post-study visit. The genotypes of a volunteer with an elevated CPK level were SLCO2B1 c.935G>A (rs12422149) AA, SLCO2B1 c.1457C>T (rs2306168) CC, SLCO1B1 *1b/*1b and ABCG2 c.421C>A (rs2231142) CA.
Discussion
This study investigated the effect of genetic polymorphisms in SLCO2B1 on the lipid-lowering efficacy of rosuvastatin in healthy adults with elevated LDL cholesterol. We demonstrated that volunteers with SLCO2B1 c.935G>A (rs12422149) genotype showed significantly lower mean % changes in LDL (62.8% (GG) versus 50.6% (GA) versus 49.3(AA), p = 0.012) and apoB (52.1% (GG) versus 42.8% (GA) versus 42.8(AA), p = 0.036) levels than those with wild-type did.
Previous studies have reported a varied association between SLCO2B1 polymorphisms and systemic exposure of drugs. Whereas SLCO2B1 c.1457C>T (rs2306168) polymorphism was associated with a reduction in systemic exposure to fexofenadine [area under the curve (AUC): 1110 AE 347 ng hr/ mL (CT + TT) versus 1762 AE 542 ng hr/mL (CC)] [7] and celiprolol [AUC: 1547 ng hr/mL (CC) versus 1097 ng hr/mL (CT) versus 775 ng hr/mL (TT)] [6] , the effect of SLCO2B1 polymorphism on montelukast was not clearly demonstrated. Mougey et al. [9] reported that c.935G>A (rs12422149) polymorphism was associated with a decrease in the plasma montelukast concentrations [square root-transformed concentration:
3 AE 1 ng/mL (GA) versus 7 AE 0.9 ng/mL (GG)], but subsequent studies could not demonstrate significant effect of c.935G>A (rs12422149) polymorphism on montelukast pharmacokinetics. [10] [11] [12] Based on previous in vitro and in vivo studies, polymorphisms in intestinal SLCO2B1 attenuated uptake activity to varying degrees, decreasing systemic exposure to substrate drugs.
To our knowledge, this study was the first to demonstrate that genetic polymorphisms in SLCO2B1 can affect the lipid-lowering efficacy of rosuvastatin. We found that SLCO2B1 c.935G>A (rs12422149) polymorphism attenuated the effects of rosuvastatin on LDL and apoB levels. This finding can be explained by a combined effect of decreased uptake activity of SLCO2B1 in the intestine and liver. Reduced activity of the intestinal and hepatic OATP2B1 transporters likely resulted in a reduction in drug absorption into the circulation and subsequent transport into the liver, thereby lowering the concentration of rosuvastatin in hepatocytes and diminishing its lipid-lowering efficacy. Regarding the known genetic polymorphisms in SLCO1B1 and ABCG2, our results were consistent with previous reports: the ABCG2 c.421C>A (rs2231142) polymorphism increased the lipid-lowering effect of rosuvastatin [14, 17] , whereas SLCO1B1 polymorphism did not show a clear effect on the action of rosuvastatin [17, 19] .
Interestingly, none of the genetic polymorphisms examined in this study were associated with a change in trough concentrations of rosuvastatin, despite their association with reduced lipid-lowering efficacy. We believe that a trough concentration measured at a single time-point does not fully reflect the overall systemic exposure of rosuvastatin. Our speculation is supported by the previous reports that ABCG2 c.421C>A (rs2231142), a well-known polymorphism to increase the systemic exposure of rosuvastatin [16, 20, 21] , does not alter the trough level of rosuvastatin. Of note, compared to the other volunteers, one volunteer of SLCO1B1 *17/*17 genotype exhibited a much higher trough level of 18.8 lg/mL. Although the comparison between SLCO1B1 wild-type and variant (homozygous and heterozygous) genotypes did not show a significant difference, we believe that the SLCO1B1 activity in this volunteer with homogeneous variant type was significantly reduced, resulting in a higher plasma trough concentration.
In this study, two cases of musculoskeletal pain and one case of elevated CPK were reported which were known as adverse events of statins. Although an association between SLCO1B1 c.521T>C (rs4149056) and statin-induced myopathy or elevation of CPK has been reported in many studies [22] [23] [24] [25] , the volunteers who reported musculoskeletal pain or elevated CPK in our study did not have SLCO1B1 c.521T>C (rs4149056) or any common polymorphisms in SLCO2B1 or ABCG2 genes.
In summary, we demonstrated an association between SLCO2B1 c.935G>A (rs12422149) polymorphism and a reduction in the lipid-lowering efficacy of rosuvastatin. Because this study was conducted in a small number of volunteers, the result of this study does not allow us to draw firm conclusions. A study with a larger sample size is warranted to confirm our findings. Also, the association of genetic 
